Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 15/20 | 0.50 |
| ▸ | PDE4A | P27815 | 14/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.48 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3120647 | 0.96 | PDE4A (0.53) | PDE4DPDE4APDE4BPDE4CLPAR1 | |
| SCHEMBL3129095 | 0.96 | PDE4A (0.56) | PDE4DPDE4APDE4BPDE4CLPAR1 | |
| SCHEMBL3131336 | 0.91 | PDE4A (0.53) | PDE4DPDE4APDE4BPDE4CLPAR1 | |
| SCHEMBL3130976 | 0.88 | PDE4D (0.44) | PDE4DPDE4APDE4BPDE4CLPAR1 | |
| SCHEMBL3128910 | 0.88 | PDE4A (0.58) | PDE4DPDE4APDE4BPDE4CLPAR1 | |
| SCHEMBL3129306 | 0.88 | PDE4A (0.56) | PDE4DPDE4APDE4BPDE4CLPAR1 | |
| SCHEMBL3215234 | 0.88 | PDE4B (0.40) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL3216063 | 0.87 | PDE4B (0.46) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL3120710 | 0.87 | L3MBTL1 (0.51) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL3120711 | 0.86 | RXRA (0.49) | PDE4DPDE4APDE4BPDE4CLPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | claimed |
| WO-2010003084-A2 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-01-07 | — | — | WO | claimed |
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010003084-A2 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE3B | PDE4D 9/4885PDE4A 1/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.